Specifically, post hoc analyses of safety findings from the short-term controlled cariprazine studies in schizophrenia [20–22] showed a dose-response relationship for some TEAEs and clinical laboratory values including akathisia, extrapyramidal disorder, CPK elevations, transaminase elevations, and increases in blood pressure [36]. Here, PIK3C2A is linked to schizophrenia.